Working… Menu

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03278028
Recruitment Status : Completed
First Posted : September 11, 2017
Results First Posted : March 29, 2019
Last Update Posted : April 9, 2019
Information provided by (Responsible Party):
Aclaris Therapeutics, Inc.

Brief Summary:
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

Condition or disease Intervention/treatment Phase
Common Wart Drug: A-101 Topical Solution Drug: A-101 Vehicle Solution Phase 2

Detailed Description:

The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

The secondary objectives of this study are to evaluate the clinical effect of A-101 when applied to all treated Warts (Target Warts plus Non-Target Warts) twice a week, duration of response in all treated Warts (Target Warts plus Non-Target Warts), and safety of A-101.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts
Actual Study Start Date : July 13, 2017
Actual Primary Completion Date : March 1, 2018
Actual Study Completion Date : March 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Arm Intervention/treatment
Experimental: Active
A-101 Topical Solutions
Drug: A-101 Topical Solution
A-101 Topical Solution

Placebo Comparator: Vehicle
Drug: A-101 Vehicle Solution
A-101 Vehicle Solution

Primary Outcome Measures :
  1. Physician's Wart Assessment [ Time Frame: Day 57 ]

    Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated.

    1. Near Clear: A visible wart that is less than 3 mm in maximal diameter (or length)
    2. A visible wart ≥ 3 mm and < 6 mm in maximal diameter (or length)
    3. A visible wart ≥ 6 mm in maximal diameter (or length)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study.
  • Male or female ≥ 8 years old.
  • Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization.
  • Woman of childbearing potential (WOCBP) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study.
  • Subject is non-pregnant and non-lactating.
  • Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target and Non-Target Warts or which exposes the subject to an unacceptable risk by study participation.
  • Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria:

  • Subject has clinically atypical warts on the trunk or extremities.
  • Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.)
  • Subject has a history of Human Immunodeficiency Virus (HIV) infection
  • Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to Visit 1
  • Subject has a history of sensitivity to any of the ingredients in the study medications.
  • Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.
  • Participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred with 30 days prior to Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03278028

Layout table for location information
United States, Arizona
Aclaris Investigational Site
Glendale, Arizona, United States, 85308
United States, Arkansas
Aclaris Investigational Site
Fort Smith, Arkansas, United States, 72916
United States, California
Aclaris Investigational Site
Encinitas, California, United States, 92024
Aclaris Investigational Site
Los Angeles, California, United States, 90045
United States, Colorado
Aclaris Investigational Site
Denver, Colorado, United States, 80210
United States, Nebraska
Aclaris Investigational Site
Omaha, Nebraska, United States, 68144
United States, New Mexico
Aclaris Investigational Site
Albuquerque, New Mexico, United States, 87106
United States, New York
Aclaris Investigational Site
Rochester, New York, United States, 14623
United States, South Carolina
Aclaris Investigational Site
High Point, South Carolina, United States, 27262
United States, Tennessee
Aclaris Investigational Site
Knoxville, Tennessee, United States, 37922
Aclaris Investigational Site
Nashville, Tennessee, United States, 37215
United States, Texas
Aclaris Investigational Site
College Station, Texas, United States, 77845
Aclaris Investigational Site
Houston, Texas, United States, 77004
United States, Utah
Aclaris Investigational Site
Salt Lake City, Utah, United States, 84117
United States, Virginia
Aclaris Investigational Site
Lynchburg, Virginia, United States, 24501
Aclaris Investigational Site
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Aclaris Therapeutics, Inc.
Layout table for investigator information
Study Director: Stuart D Shanler, MD Aclaris Therapeutics
  Study Documents (Full-Text)

Documents provided by Aclaris Therapeutics, Inc.:
Study Protocol  [PDF] November 20, 2017
Statistical Analysis Plan  [PDF] December 1, 2017

Layout table for additonal information
Responsible Party: Aclaris Therapeutics, Inc. Identifier: NCT03278028    
Other Study ID Numbers: A-101-WART-203
First Posted: September 11, 2017    Key Record Dates
Results First Posted: March 29, 2019
Last Update Posted: April 9, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Pharmaceutical Solutions